The Fanconi anemia (FA) protein FANCF is an essential component of a nuclear core complex that protects the genome against chromosomal instability, but the specific function of FANCF is still poorly understood. Based upon the homology between human and Xenopus laevis FANCF, we carried out an extensive mutagenesis study to examine which domains are functionally important and to gain more insight into the function of FANCF. In contrast to previous suggestions, we show that FANCF does not have a ROM-like function. We found that the C terminus of FANCF interacts directly with FANCG and allows the assembly of other FA proteins into a stable complex. The N terminus appears to stabilize the interaction with FANCA and FANCG and is essential for the binding of the FANCC/FANCE subcomplex. We identified several important amino acids in this N-terminal region but, surprisingly, many amino acid changes failed to affect the function of the FANCF protein. Our data demonstrate that FANCF acts as a flexible adaptor protein that plays a key role in the proper assembly of the FA core complex.
Fanconi anemia (FA) 1 is an autosomal recessive chromosomal instability syndrome. The clinical phenotype of FA patients is characterized by congenital abnormalities, progressive bone marrow failure, and a predisposition to cancer; particularly acute myeloid leukemia and squamous cell carcinoma (1, 2) . The spontaneous cytogenetic aberrations specific for FA cells are exacerbated upon treatment with DNA cross-linking agents, such as mitomycin C (MMC) and diepoxybutane, which suggests a DNA maintenance defect particularly in the handling of cross-link damage.
To date, somatic cell fusion studies have demonstrated 11 FA complementation groups (A-C, D1, D2, E-G, I, J, L) (3) and eight of the FA-associated genes have been identified: FANCA, (4 -12) . These FA genes encode orphan proteins and no functional domains have been found in their primary amino acid sequences, except for a RING finger in FANCL (10) and multiple TPR motifs in FANCG (13) . In FANCF a region with homology to RNA-binding protein ROM has been suggested to provide a clue for its function (5) .
FANCC, FANCD1/BRCA2, FANCD2, FANCE, FANCF, FANCG, and FANCL
FANCA, FANCC, FANCE, FANCF, FANCG, and FANCL assemble in a nuclear core complex (10, 14 -17) , in which FANCG binds directly to FANCA and FANCF and FANCC binds directly to FANCE (15, 16) . The nuclear core complex is essential for the monoubiquitination of FANCD2 (18) and this modified form of FANCD2 colocalizes with BRCA1, RAD51 (19) , and PCNA (20) in foci that also contain other DNA repair proteins. Nevertheless, it is still unknown how monoubiquitinated FANCD2 is involved in DNA repair and MMC resistance. Recently, biallelic mutations in BRCA2 have been found in cell lines derived from FA-D1 patients, adding BRCA2 to the list of FA proteins (8) . The BRCA proteins are known to be involved in a multitude of biological functions including DNA repair, recombination, cell cycle control, and transcription (21) . BRCA2 appears to be directly linked to the repair of double-stranded breaks (DSBs) by homologous recombination (22) . FANCD2 has also been identified as a target of the ataxia telangiectasia (AT) signaling pathway (23) and seems to be functionally connected to the RAD50/MRE11/NBS1 (RMN) protein complex (24, 25) , which plays an important role in the repair of DSBs (26) . Taken together, these data suggest that the FA proteins serve to maintain genomic stability and integrity, in concert with other protein complexes.
FANCF plays an important role in the FA pathway and its functional disruption seems to be involved in specific types of cancer, as suggested from the hypermethylation of the FANCF promoter in a subset of ovarian, oral, lung, and cervical cancers (27) (28) (29) . Nevertheless, the function of FANCF is still poorly understood. Patient-derived mutant forms of FA proteins and structure/function analysis of FANCA, FANCC, and FANCG have been informative in finding important functional residues (30 -34) , but for FANCF this information is lacking, since none of the FA-F patients have missense mutations that could provide insight into its function (5) . For this reason, we started a site-directed mutagenesis study to obtain more information about functional domains in the FANCF protein. Because such domains are expected to be relatively conserved during evolution, we searched for FANCF homologs in lower vertebrates that might highlight important residues in FANCF. We found a X. laevis homolog of FANCF (xFANCF), which has a rela-tively low overall homology with human FANCF. However, two relatively conserved regions were located at the N and C terminus. Based upon this conservation we generated a large panel of FANCF mutants and identified several functionally important amino acids and domains in FANCF. This study reveals that FANCF is an adaptor protein that plays a key role in the proper assembly of the FA core complex. To be able to perform this function the N terminus of FANCF interacts with the FANCC/FANCE subcomplex, whereas the C terminus binds to the FANCA/FANCG subcomplex.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection-Epstein-Barr virus (EBV)-transformed lymphoblasts were cultured in RPMI 1640 media supplemented with 1 mM glutamine (Invitrogen) and 10% fetal calf serum (Invitrogen). Selection medium to obtain stable cell lines also contained hygromycin B (100 g/ml; Roche Applied Science). For stable expression lymphoblastoid cell lines were transfected by electroporation using an ECM830 electrosquareporator (BTX, San Diego, CA). The MMC-induced growth inhibition assays were performed as previously described (35) (36) .
Generation of FANCF Mutant Constructs-The FANCF mutant constructs were generated by PCR with oligonucleotides encoding the amino acid substitutions or deleted regions of the FANCF sequence. We used as a template the FANCF cDNA clone 10 obtained by expression cloning (5) . The FANCF mutant R47AϩF48A was made using the QuikChange site-directed mutagenesis kit (Stratagene) according to the manufacturer's instructions. All FANCF mutants have been analyzed by sequencing to confirm that the desired changes had occurred and to exclude the presence of other PCR derived alterations. The mutants were subcloned into the expression vector pCEP4 (Invitrogen) and transfected in FA-F lymphoblasts, EUFA698. FANCF mutants 1-15del, and delC31, and wild-type FANCF-FLAG were also subcloned into the expression vector pIRESneo (Clontech, Palo Alto, CA) to generate stable cell lines. Expression of the mutant proteins in the stable cell lines was confirmed by immunoprecipitation and immunoblotting with FANCF-specific antibodies.
Sequence Analysis-FANCF mutants and the X. laevis FANCF IM-AGE clone 3200942 (obtained from HGMP Resource Centre, Cambridge, UK), were subcloned in pBluescript SK-and were sequenced with CY5.5-labeled T7 and T3 primers using a Thermo Sequenase primer cycle sequencing kit (Amersham Biosciences). Products were analyzed on a Visible Genetics automatic DNA sequencer (Visible Genetics Inc, Toronto, Ontario, Canada).
Yeast Two-hybrid Analysis-The MATCHMAKER Two-Hybrid System 3 (Clontech) was used according to the manufacturer's instructions as previously described (15) . In brief, bait and prey constructs were sequentially transformed into AH109 yeast cells and selected on -TrpLeu-His-Ade medium. The resulting colonies were tested for ␤-galactosidase expression with 5-bromo-4-chloro-3-indolyl-␤-D-galactopyranoside (X-gal). To confirm interactions a yeast-mating assay was used where constructs were transformed separately into two different yeast strains and mating cultures plated onto selection medium as above. All constructs were tested for self-activation against a series of control plasmids and expression of the mutant proteins was verified by immunoblotting.
Mammalian Two-and Three-hybrid Analysis-Human embryonic kidney cells 293, either untransfected or stably transfected with wild type or mutant (L554P) FANCC were plated onto 6-well plates. After 48 h, the cells were transiently transfected with FANCE cDNA fused to the GAL-4 activation domain (pVP16; Clontech) and the indicated FANCF constructs fused in-frame to the GAL4 DNA binding domain (pM; Clontech) (1 g of each), together with a GAL4-driven reporter plasmid (G5E1bLUC, 0.2 g). The luciferase activity was monitored after 24 h using a Dual-Luciferase Reporter Assay System (Promega) and a single tube luminometer (DLReady, Berthold Detection Systems), according to the manufacturer's instructions. All GAL4 constructs were sequenced to confirm the correct reading frame and each experimental data set was performed in triplicate to overcome the variability inherent to transfections. Transient expression of the FANCF constructs and stable expression of FANCC were confirmed by immunoblotting with FANCF and FANCC-specific antisera.
Subcellular Fractionation, Immunoprecipitation, and Immunoblotting-Nuclear and cytoplasmic fractions of the lymphoblastoid cell lines were obtained as described previously (17) . Cell extracts (ϳ10 7 cells) were prepared in lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl and 1% Nonidet P-40 supplemented with protease inhibitors) and subjected to immunoprecipitation using the indicated antibodies, as previously described (14) . Anti-FLAG M2 affinity gel (Sigma) was used to immunoprecipitate FLAG-tagged proteins. Immunoprecipitates or lysates were then separated on 8% SDS-polyacrylamide gels, transferred to polyvinylidene difluoride membranes, and specific proteins were detected by immunoblotting with the indicated antibodies.
RESULTS
Homology between the Human and Xenopus FANCF Proteins-Since functionally important amino acids are well conserved between species, we searched several databases for FANCF homologs to obtain clues about functional domains. In the NCBI data base an IMAGE clone (3200942) was found, which represented the full-length Xenopus laevis homolog of FANCF (xFANCF). The cDNA was sequenced, and the predicted protein was aligned with the human FANCF sequence (Fig. 1) . The overall homology between both sequences appeared to be limited (27% identity, 49% similarity) and dispersed over the whole molecule. However, relatively high sequence conservation was found in both the N-and C-terminal regions of the protein. To test if this limited homology was sufficient to function in a human background, FLAG-tagged xFANCF was transfected into a cell line from an FA-F patient (EUFA698). Unlike the human protein, xFANCF was unable to complement the MMC hypersensitivity of the cells, despite of its proper expression (Fig. 2) . The untagged xFANCF protein was also unable to complement the MMC defect in FA-F cells (data not shown), indicating that xFANCF is not able to restore the human FA pathway.
The FANCF Region Homologous to ROM Is Not Conserved and Not Essential for Function-FANCF was first described as The black-shaded residues are identical, and the gray-shaded residues are similar between human and Xenopus FANCF. The box shows the region homologous to the prokaryotic RNA-binding protein ROM. The asterisks point out the amino acids essential for RNA binding activity in ROM, and the triangles indicate the amino acids that were mutated in the ROM homologous region. The N-and Cterminal deletion mutants that were generated are also indicated. GenBank TM accession number for xFANCF: AY547288. a novel protein with homology to the prokaryotic RNA-binding protein ROM (5) . The sequence alignment shows that the FANCF region homologous to ROM (amino acids 145-209) is not well conserved between human and Xenopus FANCF. Furthermore, the amino acids essential for RNA binding (Gln-166 and Arg-173) are not identical in xFANCF. To further study this region, Arg-173 was changed into alanine and the mutant protein was tested for its ability to complement the MMC hypersensitivity of FA-F cells. Although this amino acid change abolished RNA binding in ROM (37), it did not have an effect on the activity of FANCF (Fig. 3) . Similarly, FANCF mutants of the glutamic acid that is identical between hFANCF and ROM (E172A and E172P) were still functional. These data suggest that the FANCF region homologous to ROM is unlikely to have an essential ROM-like function.
The C Terminus of FANCF Binds Directly to FANCG-Relatively high sequence conservation was found in the C terminus of FANCF (Fig. 1) . To study the function of this conserved region, several deletion constructs were generated and tested for their ability to complement the MMC hypersensitive phenotype of FA-F cells. Surprisingly, FANCF mutants with Cterminal deletions of 23, 31, or 40 amino acids all complemented the MMC hypersensitivity of FA-F cells (Fig. 4A ), although the survival curves were slightly shifted toward a higher sensitivity when more amino acids were deleted. Consistent with the notion that FANCD2 monoubiquitination is required for MMC resistance, FA-F cells transfected with the delC31 mutant expressed monoubiquitinated FANCD2 under normal conditions and after MMC treatment (data not shown). Co-immunoprecipitation experiments showed that the FANCF deletion mutants had a reduced interaction with FANCA and FANCG when compared with wild-type FANCF (Fig. 4B ). Deletion of 31 or 40 amino acids completely abolished the interaction in this assay. Since FANCF has been shown to interact directly with FANCG (15, 38), we tested the interaction between FANCG and the deletion mutants in a yeast two-hybrid assay. In both co-transformation and mating experiments the mutants with a deletion of 31 or 40 amino acids had a strongly reduced FANCG binding (Table I ). These results demonstrate that the last 31-40 amino acids in the C terminus of FANCF are important for the direct interaction with FANCG. By interfering with the binding to FANCG, the interaction with FANCA is also disturbed, indicating that the C terminus of FANCF is binding the FANCA/FANCG subcomplex through FANCG.
The N Terminus of FANCF Is Involved in Binding of the FANCC/FANCE Subcomplex-We next evaluated the function of a deletion mutant that lacked the highly conserved first 15 amino acids of FANCF. The mutant FANCF protein was not able to complement the MMC hypersensitivity of FA-F cells, despite its proper expression and nuclear localization (Fig. 5 ). Although this mutant protein interacted with FANCA and FANCG, the interaction was weak compared with that of wildtype FANCF (Figs. 4B and 8B).
Unlike wild-type FANCF, which can be immunoprecipitated in a complex with FANCE, we did not detect any FANCE in a complex with the N-terminal deletion mutant of FANCF using antisera against FANCE (Fig. 6A) . Furthermore, the mutant protein did not restore the interaction among FANCE, FANCA, and FANCG that is observed in wild-type cells. Similarly, the C-terminal deletion mutant lacking the last 31 amino acids was unable to bind FANCE and could not form a stable FA complex (Fig. 6A) . In a reciprocal experiment, FANCC and FANCE did not co-immunoprecipitate with the N-terminal deletion mutant (Fig. 6B) proteins associate in the core complex. Previously, no direct interaction between FANCF and FANCC or FANCE has been found in yeast two-hybrid assays (15, 38) , suggesting that the association with FANCC and FANCE is indirect. We investigated these interactions in a mammalian two-hybrid assay and also in this assay FANCF did not interact with FANCC or FANCE (Fig. 6C) , whereas an interaction between FANCC and FANCE was observed. We then sought to determine if the N terminus of FANCF might be involved in the binding of this FANCC/FANCE subcomplex, using a mammalian three-hybrid (M3H) system, with 293 cells stably overexpressing FANCC. In this assay, we observed a strong induction of the reporter gene when FANCF was cotransfected with FANCE ( Fig. 6D) , indicating that FANCC acts as a molecular bridge between FANCF and FANCE. As a control experiment, we used a 293 cell line stably overexpressing FANCC mutant L554P, which is defective in binding FANCE (16, 38) and found no interaction between FANCF and FANCE (data not shown). To further extend these observations, we tested the FANCF N-and C-terminal deletion mutants in the M3H assay. In agreement with our co-immunoprecipitation experiments, the FANCF mutant 1-15del completely failed to interact with FANCE, whereas the FANCF mutant delC31 had a reduced interaction (Fig. 6D) . Collectively, these observations indicate that the first 15 amino acids of FANCF are essential for the direct binding of the FANCC/FANCE subcomplex. Furthermore, they demonstrate that this interaction also partially depends on the C-terminal part of the FANCF protein.
The N Terminus of FANCF Contains Several Residues Essential for Its Function-Several missense mutants were generated to delineate amino acids in the N-terminal region of FANCF essential for its interaction with the other FA proteins and for its ability to complement the MMC defect in FA-F cells (see Table II ). Secondary structure prediction programs indicate that the first 15 amino acids of human FANCF form an 
Mating assays 1 and 2 amphipathic ␣-helix (Fig. 7) , with a strong negative charge at one side of the helix (Glu-2, Asp-9, and Glu-13). In the Xenopus homolog a similar structure was predicted, with Glu-6, Asp-9, and Glu-13 at the negative side of the helix.
These negatively charged amino acids were either changed into alanines (E2AϩD9AϩE13A) or replaced by positively charged lysines (E2KϩD9KϩE13K) and the mutants were tested for their ability to complement the MMC hypersensitivity of FA-F cells, and for their ability to interact with FANCA. Both mutants were able to complement the MMC defect (Fig. 8A) , but like the N-terminal deletion mutant, the E2KϩD9KϩE13K mutant appeared to have a reduced interaction with FANCA (Fig. 8B) . Since the C terminus of FANCF is also involved in the interaction with FANCA (Fig. 4B) , we tested mutants with a combination of mutation and deletions to determine if the N-and C-terminal conserved regions of FANCF act in concert. When the last 23 C-terminal amino acids were removed, the E2AϩD9AϩE13A mutant was still biologically active, whereas the E2KϩD9KϩE13K mutant became inactive (Fig. 8C) . We then removed 31 C-terminal amino acids of these mutants and found that this completely abolished the activity of both mutants (Fig. 8D) . Thus, reversing the charges of the residues in the FANCF ␣-helix is more disruptive than neutralizing the positively charged residues. We infer that the three negatively charged amino acids in the first N-terminal ␣-helix of FANCF are functionally important and that FANCF has partially interdependent functional terminal domains.
The hydrophobic side of the N-terminal ␣-helix contains three conserved leucines (Leu-5, Leu-8, and Leu-15). When these leucines were replaced by alanines, the mutant protein was functional in an MMC test (Fig. 9A) . However, this mutant was totally inactivated upon removal of the 31 C-terminal amino acids (Fig. 9A) , hinting that the conservation at the hydrophobic side of the helix is of functional significance. We then examined the ability of the FANCF mutant L5AϩL8AϩL15A (with an intact C terminus) to interact with the FANCC/FANCE subcomplex in the M3H assay and found that this mutant failed to activate transcription of the luciferase reporter gene (Fig. 9C) . These results suggest that the three leucines residues are involved in the direct binding of the FANCC/FANCE subcomplex.
We further investigated N-terminal mutants, in which combinations of the conserved arginine (Arg-10) or phenylalanine (Phe-11) residues were modified. All the single mutants were able to complement the MMC hypersensitivity of FA-F cells (Table II) and displayed a normal interaction with FANCA (Fig. 8B) . These mutants were still functional when the C-terminal 31 amino acids were removed (Table II) . However, a double mutant in which both Arg-10 and Phe-11 were changed into alanine (R10AϩF11A) had a reduced biological activity, but only in combination with a C-terminal deletion of 31 amino acids (Fig. 9B) . A possible explanation for the partial inactivation of the protein is the prediction of a similar ␣-helix (amino acids 31-48), in which a conserved arginine (Arg-47) and phenylalanine (Phe-48) are found (Fig. 7) . These amino acids might be able to partially compensate for the amino acid changes in the first ␣-helix. To test this hypothesis, we constructed a mutant in which the arginines and phenylalanines in both helices were replaced by alanines (R10AϩF11AϩR47AϩF48A). When combined with a deletion of the C terminus, this mutant was totally inactive (Fig. 9B) . A mutant in which only Arg-47 and Phe-48 were changed (R47AϩF48A) was functional (Fig. 9B) . These results indicate that the conserved arginines (Arg-10 and Arg-47) and phenylala- nines (Phe-11 and Phe-48) in the first and second ␣-helix may form a functional unit. The M3H assay was used to show that the R10AϩF11AϩR47AϩF48A mutant (with an intact C terminus) was unable to interact with the FANCC/FANCE subcomplex (Fig. 9C) , suggesting that these arginine and phenylalanine residues participate in this direct interaction. In order to investigate whether the two predicted N-terminal ␣-helices are really being formed and function as a unit, several leucine to proline mutants were made to disrupt the helical structure of this region (Table II) . The disruption of the first ␣-helix by substitution of Leu-8 or Leu-14 as well as the disruption of the second ␣-helix by substitution of Leu-41 interfered with the biological activity of the protein, but again only when the C-terminal 31 amino acids were removed. As a control, we replaced Leu-14 by alanine and deleted its C terminus, and found that this did not affect the function of the protein. These results imply that the two N-terminal ␣-helices in FANCF form a functionally important structure, which cooperates with the C terminus of the protein.
A serine and threonine stretch (Ser-18, Ser-19, Thr-20, Thr-21) is located just after the first N-terminal ␣-helix. To investigate the functional significance of this region we changed these amino acids into alanines. This mutant was again inactive after removal of its C terminus (Fig. 9D) . However, a mutant (S18A) in which only the conserved Ser-18 was changed to an alanine appeared to be functional (Fig. 9D) . Subsequent analysis of these FANCF mutants (with an intact C terminus) in the M3H assay showed that only the mutant S18A was able to activate the luciferase reporter gene (Fig. 9E) . These data suggest that the serine and threonine stretch is of functional importance and is involved in the binding of the FANCC/ FANCE subcomplex.
Amino Acids 76 -84 Are Not Essential for the Function of FANCF-FA-F patient EUFA698 has a 23-bp deletion in the FANCF gene resulting in a frameshift at codon 77 (5). Since the deleted region is poorly conserved between human and Xenopus FANCF, we tried to overcome the defect by selection for a phenotypic revertant in vitro. After long term culture of a lymphoblastoid cell line from patient EUFA698 in the presence of 15 nM MMC an MMC-resistant cell line was obtained. Sequence analysis indicated that a deletion of nucleotide 225 (225delT) had restored the FANCF reading frame in one allele of the reverted cell line (Fig. 10) . In the mutant protein, Pro-76 is changed into a glutamine whereas amino acids 77-84 are absent. This FANCF mutant is expressed and has a normal interaction with FANCA (Fig. 10) . These data therefore indicate that amino acids 76 -84 are not essential for the complementing activity of the FANCF protein and support the idea that the structure of FANCF is rather flexible.
DISCUSSION
Highly conserved amino acids are generally thought to be critical for a protein's function. By using an extensive sitedirected mutagenesis approach we have investigated the functional importance of amino acids that are conserved between human and X. laevis FANCF. Our results demonstrate that the C terminus of FANCF binds directly to FANCG and is required for stable interaction with FANCA, FANCC, and FANCE. Further- more, we found that the N terminus of FANCF is essential for the direct interaction with the FANCC/FANCE subcomplex, and is important for stabilizing the complex formation with FANCA and FANCG. This study shows that FANCF is an adaptor protein, which keeps the other components of the FA core complex together in such a way that they can perform their function.
A direct interaction between FANCF and FANCG has been demonstrated using the yeast two-hybrid system (15) and the C terminus of FANCF (amino acids 243-374) was shown to be essential for this interaction (38) . In the current study, we found that the interaction site is specifically located in the strongly conserved last 31 amino acids (amino acids 343-374) of FANCF and that this particular region provides stability to the FA core complex. Surprisingly, the C-terminal deletion mutants were still able to complement the MMC hypersensitivity of FA-F cells and to support the monoubiquitination of FANCD2. The ability of the FANCFdelC31 mutant to complement FA-F cells was not a result of overexpression of this protein, since low expression levels of this mutant protein by a leaky inducible vector (pMEP4) or by stable integration (pIRESneo) still corrected the MMC hypersensitivity. 2 Since the mutant FANCFdelC31 also corrects the MMC hypersensitivity of FA-F patient cell line EUFA1228, 2 the complementing activity of this mutant is also not cell line-dependent. We infer from our results that the FANCFdelC31 mutant protein has a reduced affinity for the other members of the complex, undetectable in co-immunoprecipitation experiments because of the stringent conditions of this assay, but sufficient for a functional FA pathway. This conclusion is supported by our data showing an interaction between the FANCFdelC31 mutant and the FANCC/FANCE subcomplex in the mammalian three-hybrid assay, which was undetectable in co-immunoprecipitation experiments.
The first 15 amino acids of FANCF are predicted to form an ␣-helix sharing 60% homology with Xenopus FANCF. This region is essential for the function of FANCF, since a FANCF mutant in which these amino acids were deleted failed to correct the MMC hypersensitivity of EUFA698 cells. This FANCF mutant appeared to have a normal nuclear localization and a reduced interaction with FANCA and FANCG, indicating that this particular region in FANCF is not directly involved in the nuclear targeting of FANCF, but crucial for the stable binding to FANCA and FANCG. Interestingly, the FANCF mutant 1-15del failed to co-precipitate with FANCC and FANCE, suggesting that this particular N-terminal region in FANCF is required for the presence of FANCC and FANCE within the FA core complex. The mammalian three-hybrid system confirms this finding and provides strong evidence for direct interaction between the first 15 amino acids of FANCF and the FANCC/FANCE subcomplex. Fold induction is expressed relative to the luciferase activity obtained with the pVP16-AD-FANCE vector alone. D, FANCF mutant in which Ser-18, Ser19, Thr-20, and Thr-21 are changed into alanine is not able to complement the MMC hypersensitive phenotype of EUFA698 cells after removal of the C-terminal 31 amino acids. E, mammalian three-hybrid assay showing interaction of the FANCC/FANCE subcomplex with wild-type FANCF and FANCF mutant S18A, which is lost in the FANCF mutant S18A/S19A/T20A/T21A (SSTT/A).
To identify functionally relevant residues in the N terminus of FANCF, we generated several mutations in the first 48 amino acids that contain two predicted ␣-helices. Surprisingly, we could not obtain inactive or partially functional mutants without the additional removal of the last 31 amino acids when we assayed for the ability to complement the MMC hypersensitive phenotype of FA-F cells. This implies that the FANCA-FANCG interaction needs to be disturbed before amino acid substitutions in the N terminus of FANCF show an effect in this assay. However, when tested in the M3H assay, mutations in the N terminus of FANCF were sufficient to interfere with the binding of the FANCC/FANCE subcomplex. Apparently, the binding of FANCA and FANCG to the C terminus of FANCF stabilizes the interaction of factors that bind to the N terminus of FANCF, in particular the FANCC/FANCE subcomplex. By removing the C terminus of the FANCF protein we interfered with this stabilizing effect. In the mammalian threehybrid assay we do not need to interfere with the binding of the FANCA/FANCG subcomplex, since in this assay FANCA and FANCG are not present. What we have essentially tested in the mammalian three hybrid assay and the MMC test with the C-terminally truncated N-terminal mutants is the same; the interaction with the FANCC/FANCE subcomplex in the absence of the FANCA/FANCG subcomplex. Accordingly, the results of both assays are the same. The detection of a weak interaction between FANCA and FANCE (Ref. 16 and Fig. 6A ) and between FANCA and FANCC (14) in co-immunoprecipitation experiments on lysates of FA-F cells indicates that these FA proteins have some affinity for each other, but that these interactions need to be stabilized by the presence of FANCF. The results of our experiments suggest that binding of the FANCC/FANCE subcomplex to the N terminus of FANCF (in case of the C-terminal deletion mutants) or binding of the FANCA/FANCG subcomplex to C terminus of FANCF (in case of the N-terminal missense mutants) is sufficient to activate the FA pathway.
From the non-functional mutants we identified four critical regions defined by a group of residues essential for the proper function of FANCF. One region consists of 3 consecutive negatively charged residues (Glu-2, Asp-9, Glu-13) located at one side of the first ␣-helix. It is tempting to speculate that this region interacts through salt bridges with the 3 positively charged residues (Arg-32, Arg-39, Arg-46) located at one side of the second ␣-helix to form a functional domain. Another important region involves 3 conserved hydrophobic amino acids on one side of the first ␣-helix (Leu-5, Leu-8, Leu-15), which appear to form a binding site for the FANCC/FANCE subcomplex. The conserved arginines (Arg-10 and Arg-47) and phenylalanines (Phe-11 and Phe-48) in the first and second ␣-helix form the third critical region in the N terminus of FANCF. These 4 residues combined are also involved in the association with the FANCC/FANCE subcomplex and may either be a part of the interaction domain or stabilize this domain. A fourth critical region in the FANCF protein is formed by a stretch of serinethreonine residues in the loop region between the two ␣-helices. Although there is no evidence as yet for post-translational modification of FANCF, this specific region could be the target for phosphorylation by a serine/threonine kinase. Alternatively, these serines and threonines might be involved in protein-protein interaction through the formation of hydrogen bonds. Our data show that this particular region plays a role in the direct interaction with the FANCC/FANCE subcomplex. Finally, the FANCF region homologous to the prokaryotic RNA binding protein ROM (amino acid residues 145-209) does not seem to have an essential ROM-like function. The FANCF mutants R172A, E172P, and R173A (equivalent in ROM to amino acids Q24 and R25, respectively) did not affect the function of FANCF.
We realize that these mutagenesis studies need to be interpreted with caution, because of the risk to affect the general structure of the protein. However, since amino acid changes in the N terminus and even deletions of the C terminus of FANCF were tolerated, the FANCF structure seems to be very stable and flexible. Also the fact that a deletion of the C terminus only inactivates a subset of the N-terminal FANCF mutants indicates that it is very difficult to affect the structure of the FANCF protein. Consistent with this idea is that none of the identified FA-F patients have missense mutations in FANCF, but rather have nonsense mutations or deletions (5). Furthermore, an in vitro revertant of EUFA698 cells expresses a mutant FANCF protein that lacks amino acids 76 -84, which is still functional. The only mutation that might have changed the stucture of the FANCF protein is the N-terminal deletion mutant, since this is the only single mutant that is unable to restore the MMC hypersensitivity of FA-F cells.
Our results suggest a sequential recruitment of the FA gene products in which the FANCF protein has a key role by linking the different subcomplexes (FANCA/FANCG and FANCC/ FANCE) and possibly other components together. Therefore, we propose that FANCF acts as an adaptor protein that plays a key role in the proper assembly of the FA core complex. We infer from our and published data that FANCF stabilizes the interaction between the FANCC/FANCE subcomplex and the FANCA/FANCG subcomplex and locks the whole FA core complex in a conformation that is essential to perform its function. 
